Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cabozantinib S-malate
Cabozantinib S · 1 trial · 4 indications
Will be assessed by the Common Terminology Criteria for Adverse Events version 5.0.
| Arm | Type | Description |
|---|---|---|
| Treatment (cabozantinib, enfortumab vedotin) | EXPERIMENTAL | Patients receive cabozantinib PO QD on days 1-28 and enfortumab vedotin IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Cabozantinib S-malate | DRUG | Given PO |
| Enfortumab Vedotin | DRUG | Given IV |
| Quality-of-Life Assessment | OTHER | Ancillary studies |
| Questionnaire Administration | OTHER | Ancillary studies |
Inclusion Criteria: * Histologically-documented urothelial carcinoma (squamous differentiation or mixed cell types allowed if urothelial carcinoma is present) * Metastatic disease or unresectable locally-advanced disease * Must have received prior treatment with a checkpoint inhibitor (CPI). A CPI ...
Cabozantinib S is an investigational small molecule being studied for infiltrating bladder urothelial carcinoma with squamous differentiation, as well as locally advanced, metastatic, and unresectable urothelial carcinoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
Cabozantinib S is a kinase inhibitor, belonging to the -tinib class of drugs. It is being studied in combination with enfortumab vedotin for the treatment of urothelial cancers, including infiltrating bladder urothelial carcinoma with squamous differentiation.
Cabozantinib S is being developed by Exelixis, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol EXEL. The company is conducting a Phase 1 clinical trial of the drug in the United States.
Cabozantinib S is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing trial is actively recruiting participants in the United States.
Cabozantinib S is being studied in a single Phase 1 clinical trial, NCT04878029, titled 'Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer.' The trial is recruiting 32 participants in the United States and is not randomized or blinded.
Yes, Cabozantinib S is also known as Cabozantinib S-malate. Both names refer to the same investigational drug being developed by Exelixis, Inc. for the treatment of urothelial carcinoma.